当前位置：药药网 / 药品 / 美国NDC未完成药物数据库文件(本栏目更新到2026-3-31)
药品名称： 商品名称： 药品NDC： 上市日期： -格式:2020-5-3
注册申请号： 市场分类： 活性成分： 持证企业：
 美国NDC未完成药物数据库文件21130条(本栏目更新到2026-3-31)
药品名称(分析)
商品名
药品NDC
专利人(分析)
上市日期
活性成分
市场分类
规格(分析)
申请号
Eplerenone
BULK INGREDIENT
0009-5276
Pharmacia & Upjohn Company LLC
20140703
EPLERENONE
BULK INGREDIENT
1
0009-5276_98593b8e-f6c7-4ccb-8b48-14331c1ad999
Diflorasone Diacetate
BULK INGREDIENT
0009-5610
Pharmacia and Upjohn Company LLC
20140703
DIFLORASONE DIACETATE
BULK INGREDIENT
1
0009-5610_18630a92-6a85-47d8-bea9-2538875bfbe5
Progesterone
BULK INGREDIENT
0009-5620
Pharmacia and Upjohn Company LLC
20140703
PROGESTERONE
BULK INGREDIENT
1
0009-5620_08d1a720-1ee8-41c7-96e9-a3542159168f
botulinum toxin type A
BULK INGREDIENT
0023-1111
Allergan, Inc.
20240229
BOTULINUM TOXIN TYPE A
BULK INGREDIENT
1
0023-1111_82a2e3fc-3b5e-4277-bc5f-6450fabd6823
botulinum toxin type A
BULK INGREDIENT
0023-1111
Allergan, Inc.
19891215
BOTULINUM TOXIN TYPE A
BULK INGREDIENT
1
0023-1111_aefdd7bb-6a5b-4b73-b97f-8d65fdd2eb0a
BOTULINUM TOXIN TYPE A
DRUG FOR FURTHER PROCESSING
0023-5027
Allergan, Inc.
20241015
BOTULINUM TOXIN TYPE A
DRUG FOR FURTHER PROCESSING
100
0023-5027_c3ebe182-dd77-4faf-9135-872a34c199b0
botulinum toxin type a
DRUG FOR FURTHER PROCESSING
0023-5028
Allergan, Inc.
20241104
BOTULINUM TOXIN TYPE A
DRUG FOR FURTHER PROCESSING
200
0023-5028_b11e299c-adbd-4d27-91f0-788bcb9bc7ac
ubrogepant
DRUG FOR FURTHER PROCESSING
0023-6499
Allergan, Inc.
20191223
UBROGEPANT
DRUG FOR FURTHER PROCESSING
50
0023-6499_3373b22f-6c39-46f3-beb5-aa6a2a5bdfee
ubrogepant
DRUG FOR FURTHER PROCESSING
0023-6502
Allergan, Inc.
20191223
UBROGEPANT
DRUG FOR FURTHER PROCESSING
100
0023-6502_3373b22f-6c39-46f3-beb5-aa6a2a5bdfee
Dextromethorphan Hydrobromide, Guaifenesin, Phenylephrine Hydrochloride
BULK INGREDIENT
0031-8729
Haleon US Holdings LLC
20150901
DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN; PHENYL
EXPORT ONLY
10; 100; 5
0031-8729_16c80578-20c3-8c05-e063-6294a90a2b48
glipizide
DRUG FOR FURTHER PROCESSING
0049-1581
Roerig
20130509
GLIPIZIDE
EXPORT ONLY
5
0049-1581_711e04c2-ca24-490d-8720-176c6f0044bc
glipizide
DRUG FOR FURTHER PROCESSING
0049-1582
Roerig
20130509
GLIPIZIDE
EXPORT ONLY
10
0049-1582_711e04c2-ca24-490d-8720-176c6f0044bc
Elagolix Sodium
BULK INGREDIENT
0051-0040
AbbVie Inc.
20201113
ELAGOLIX SODIUM
BULK INGREDIENT
1
0051-0040_0454fd25-8e5a-407d-b5ef-04b22bc2c8ca
Vedolizumab
BULK INGREDIENT
0051-2638
AbbVie Inc.
20160929
VEDOLIZUMAB
BULK INGREDIENT
96000
0051-2638_4c28156d-a6b5-4dc8-8d76-f93c86f71f3b
Acetaminophen, aspirin, caffeine
DRUG FOR FURTHER PROCESSING
0067-4202
Haleon US Holdings LLC
20240101
ACETAMINOPHEN; ASPIRIN; CAFFEINE
DRUG FOR FURTHER PROCESSING
250; 250; 65
0067-4202_1b68320d-4700-4ee4-850a-8092e7642d0e
prazosin hydrochloride
DRUG FOR FURTHER PROCESSING
0069-4260
Pfizer Laboratories Div Pfizer Inc
20140901
PRAZOSIN HYDROCHLORIDE
DRUG FOR FURTHER PROCESSING
2.5
0069-4260_90f0943b-a25b-418d-b627-e9473f21b594
prazosin hydrochloride
DRUG FOR FURTHER PROCESSING
0069-4270
Pfizer Laboratories Div Pfizer Inc
20140901
PRAZOSIN HYDROCHLORIDE
DRUG FOR FURTHER PROCESSING
5
0069-4270_90f0943b-a25b-418d-b627-e9473f21b594
Ibrutinib
DRUG FOR FURTHER PROCESSING
0074-0070
AbbVie Inc.
20240314
IBRUTINIB
DRUG FOR FURTHER PROCESSING
70
0074-0070_68d5b97b-8cae-4bb7-84df-9c089bd705e4
Olaparib
DRUG FOR FURTHER PROCESSING
0074-0668
AbbVie Inc.
20180907
OLAPARIB
DRUG FOR FURTHER PROCESSING
100
0074-0668_1fdc89e3-b2da-474d-bcc7-17fe22854e06
Olaparib
DRUG FOR FURTHER PROCESSING
0074-0679
AbbVie Inc.
20180907
OLAPARIB
DRUG FOR FURTHER PROCESSING
150
0074-0679_1fdc89e3-b2da-474d-bcc7-17fe22854e06
网站地图 - 网站开发 - 网站简介 - 会员服务 - 法律声明 - 联系我们 - 药品招商频道 - 药品信息排行 - 2018年版国家基本药物目录 - 意见反馈
免责声明：以上所展示的信息由企业自行提供，内容的真实性、准确性和合法性由发布企业负责，医药网对此不承担任何责任。
相关链接：医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究　　客服热线：0575-83552251 / 13754370441  QQ客服：药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　浙公网安备:330683240604819103159
　医药代理商群１：药药网药品采购交流医药代理商群２：药药网药品采购交流2医药代理商群３：药药网药品采购交流3